All News

“Each of us has our own way of marking what cancer brings to our lives, sometimes in a simple three-letter word,” writes a woman with breast cancer.

Fewer opioids have been prescribed, but there have been more emergency room visits for pain in patients with cancer who have poor prognoses.

Assigning healthy classmates to accompany patients with cancer in their peer group to hospital visits had a positive impact on the patients’ social and emotional wellbeing.

The approval of the immunotherapy agent “has the potential to change the treatment paradigm” in high-risk, early-stage TNBC.

Most people who consume alcohol are unaware that it increases their risk of receiving a diagnosis of cancer, according to an expert.

Post-menopausal women may be at an increased risk for kidney cancer if they are diagnosed with type 2 diabetes.

An expert discusses the most common reasons his patients ask him about medical marijuana.

A survivor of prostate cancer celebrates the news that his cancer has not spread and describes how remission has made him feel.

Three different people describe similar experiences with someone who stands alongside them during their journeys.

About 25% of patients with blood cancer did not produce antibodies after being vaccinated against COVID-19.

"Hildy’s creative energy in founding and nurturing Upstage Lung Cancer has made many more people aware of the disease," one man writes.

A breast cancer survivor writes a poem about feeling adrift after treatment.

A mother credits her son’s oncology nurse for saving his life and their entire family with her smile, grace and endless commitment.

A patient with small cell lung cancer nominates writes about the woman who connected her to others with the same diagnosis.

A stage 2 breast cancer survivor uses poetry to reflect on her views about her changing body after a lumpectomy, chemotherapy and radiation.

A patient with cancer recalls his experience with group therapy started by a nurse that helped him learn more not only from her but from others in similar situations.

The FDA’s recent approval of Keytruda in combination with trastuzumab and chemotherapy in the first-line setting is an exciting change for a group of patients with certain subtypes of stomach cancer, according to an expert.

Patients with heart failure may have an increased incidence of cancer, which may be a result of similar risk factors including obesity and diabetes.

A colleague writes about an infusion nurse that has the bedside manner to make patients’ experiences with cancer a little calmer with her sense of humor and knowledge.

“My stories are my trail of crumbs leading back to my heart and my innermost thoughts,” writes a woman living with metastatic breast cancer.

From a 90-year-old man’s 3,600-mile walk to raise money for children with cancer to the death of KISS and Cinderella keyboardist Gary Corbett, here’s what’s happening in the cancer landscape this week.

CURE® offers tips to stay relaxed and healthy during the summer months.

A cancer survivor writes about the oncologist who helped him conquer the fears and anxieties of cancer treatments.

If followed, clinical trial protocols established during the COVID-19 pandemic could allow more patients participate.

The FDA’s recent approval of Rybrevant marks the first targeted therapy for a certain group of patients with non-small cell lung cancer, according to an expert at NYU Langone Health’s Perlmutter Cancer Center.

More research is needed on how a chronic lymphocytic leukemia diagnosis can affect patients and their caregivers.

A cancer survivor shares the valuable lessons she learned from the COVID-19 pandemic, almost six months after receiving her vaccination.

In this episode of the “CURE® Talks Cancer” podcast, Joey Renick opens up about his cancer journey and explains how he went on to bike 100 miles for The Leukemia and Lymphoma Society.

The Food and Drug Administration approved Keytruda plus Lenvima for patients with advanced endometrial carcinoma whose disease had progressed after previous systemic therapy and are not candidates for surgery or radiation.

The FDA will expedite the development and review of the drug combination to treat untreated intermediate- high- and very high-risk myelodysplastic syndrome.